Virus-like  ||| S:0 E:11 ||| JJ
particle-based  ||| S:11 E:26 ||| JJ
countermeasures  ||| S:26 E:42 ||| NNS
against  ||| S:42 E:50 ||| IN
Rift  ||| S:50 E:55 ||| NNP
Valley  ||| S:55 E:62 ||| NNP
fever  ||| S:62 E:68 ||| NN
virus  ||| S:68 E:74 ||| NN
Rift  ||| S:74 E:79 ||| NNP
Valley  ||| S:79 E:86 ||| NNP
fever  ||| S:86 E:92 ||| NN
virus  ||| S:92 E:98 ||| NN
( ||| S:98 E:99 ||| -LRB-
RVFV ||| S:99 E:103 ||| NNP
)  ||| S:103 E:105 ||| -RRB-
is  ||| S:105 E:108 ||| VBZ
an  ||| S:108 E:111 ||| DT
arbovirus  ||| S:111 E:121 ||| NN
that  ||| S:121 E:126 ||| WDT
causes  ||| S:126 E:133 ||| VBZ
significant  ||| S:133 E:145 ||| JJ
morbidity  ||| S:145 E:155 ||| NN
and  ||| S:155 E:159 ||| CC
mortality  ||| S:159 E:169 ||| NN
in  ||| S:169 E:172 ||| IN
both  ||| S:172 E:177 ||| DT
humans  ||| S:177 E:184 ||| NNS
and  ||| S:184 E:188 ||| CC
livestock ||| S:188 E:197 ||| NN
.  ||| S:197 E:199 ||| .
With  ||| S:199 E:204 ||| IN
increased  ||| S:204 E:214 ||| JJ
world  ||| S:214 E:220 ||| NN
travel  ||| S:220 E:227 ||| NN
and  ||| S:227 E:231 ||| CC
the  ||| S:231 E:235 ||| DT
threat  ||| S:235 E:242 ||| NN
of  ||| S:242 E:245 ||| IN
bioterrorism ||| S:245 E:257 ||| NN
,  ||| S:257 E:259 ||| ,
there  ||| S:259 E:265 ||| EX
is  ||| S:265 E:268 ||| VBZ
a  ||| S:268 E:270 ||| DT
real  ||| S:270 E:275 ||| JJ
risk  ||| S:275 E:280 ||| NN
of  ||| S:280 E:283 ||| IN
RVFV  ||| S:283 E:288 ||| NNP
spreading  ||| S:288 E:298 ||| VBG
to  ||| S:298 E:301 ||| TO
na√Øve  ||| S:301 E:307 ||| VB
geographical  ||| S:307 E:320 ||| JJ
areas  ||| S:320 E:326 ||| NNS
( ||| S:326 E:327 ||| -LRB-
Trans ||| S:327 E:332 ||| NNP
.  ||| S:332 E:334 ||| .
R.  ||| S:334 E:337 ||| NNP
Soc ||| S:337 E:340 ||| NNP
.  ||| S:340 E:342 ||| .
Trop ||| S:342 E:346 ||| NNP
.  ||| S:346 E:348 ||| .
Med ||| S:348 E:351 ||| NNP
.  ||| S:351 E:353 ||| .
Hyg. ||| S:353 E:357 ||| NNP
,  ||| S:357 E:359 ||| ,
73 ||| S:359 E:361 ||| CD
,  ||| S:361 E:363 ||| ,
1979 ||| S:363 E:367 ||| CD
,  ||| S:367 E:369 ||| ,
618 ||| S:369 E:372 ||| CD
;  ||| S:372 E:374 ||| :
MMWR  ||| S:374 E:379 ||| NNP
Morb ||| S:379 E:383 ||| NNP
.  ||| S:383 E:385 ||| .
Mortal ||| S:385 E:391 ||| NNP
.  ||| S:391 E:393 ||| .
Wkly  ||| S:393 E:398 ||| NNP
Rep. ||| S:398 E:402 ||| NNP
,  ||| S:402 E:404 ||| ,
49 ||| S:404 E:406 ||| CD
,  ||| S:406 E:408 ||| ,
2000 ||| S:408 E:412 ||| CD
,  ||| S:412 E:414 ||| ,
905 ||| S:414 E:417 ||| CD
) ||| S:417 E:418 ||| -RRB-
.  ||| S:418 E:420 ||| .
The  ||| S:420 E:424 ||| DT
introduction  ||| S:424 E:437 ||| NN
of  ||| S:437 E:440 ||| IN
RVFV  ||| S:440 E:445 ||| NNP
would  ||| S:445 E:451 ||| MD
cause  ||| S:451 E:457 ||| VB
critical  ||| S:457 E:466 ||| JJ
public  ||| S:466 E:473 ||| JJ
health ||| S:473 E:479 ||| NN
,  ||| S:479 E:481 ||| ,
agricultural  ||| S:481 E:494 ||| JJ
and  ||| S:494 E:498 ||| CC
economic  ||| S:498 E:507 ||| JJ
damage ||| S:507 E:513 ||| NN
.  ||| S:513 E:515 ||| .
Despite  ||| S:515 E:523 ||| IN
the  ||| S:523 E:527 ||| DT
clear  ||| S:527 E:533 ||| JJ
need  ||| S:533 E:538 ||| NN
for  ||| S:538 E:542 ||| IN
an  ||| S:542 E:545 ||| DT
efficacious  ||| S:545 E:557 ||| JJ
vaccine ||| S:557 E:564 ||| NN
,  ||| S:564 E:566 ||| ,
there  ||| S:566 E:572 ||| EX
are  ||| S:572 E:576 ||| VBP
no  ||| S:576 E:579 ||| DT
United  ||| S:579 E:586 ||| NNP
States  ||| S:586 E:593 ||| NNPS
( ||| S:593 E:594 ||| -LRB-
US ||| S:594 E:596 ||| NNP
)  ||| S:596 E:598 ||| -RRB-
Food  ||| S:598 E:603 ||| NNP
and  ||| S:603 E:607 ||| CC
Drug  ||| S:607 E:612 ||| NNP
Administration  ||| S:612 E:627 ||| NNP
or  ||| S:627 E:630 ||| CC
US  ||| S:630 E:633 ||| NNP
Department  ||| S:633 E:644 ||| NNP
of  ||| S:644 E:647 ||| IN
Agriculture  ||| S:647 E:659 ||| NNP
approved  ||| S:659 E:668 ||| VBD
vaccines  ||| S:668 E:677 ||| VBN
against  ||| S:677 E:685 ||| IN
RVFV ||| S:685 E:689 ||| NNP
.  ||| S:689 E:691 ||| .
To  ||| S:691 E:694 ||| TO
address  ||| S:694 E:702 ||| VB
this  ||| S:702 E:707 ||| DT
need ||| S:707 E:711 ||| NN
,  ||| S:711 E:713 ||| ,
a  ||| S:713 E:715 ||| DT
virus-like  ||| S:715 E:726 ||| JJ
particle  ||| S:726 E:735 ||| NNS
( ||| S:735 E:736 ||| -LRB-
VLP ||| S:736 E:739 ||| NNP
) ||| S:739 E:740 ||| -RRB-
-based  ||| S:740 E:747 ||| JJ
vaccine  ||| S:747 E:755 ||| NN
candidate  ||| S:755 E:765 ||| NN
was  ||| S:765 E:769 ||| VBD
developed ||| S:769 E:778 ||| VBN
.  ||| S:778 E:780 ||| .
First ||| S:780 E:785 ||| NNP
,  ||| S:785 E:787 ||| ,
a  ||| S:787 E:789 ||| DT
non-replicating  ||| S:789 E:805 ||| JJ
chimeric  ||| S:805 E:814 ||| JJ
RVF  ||| S:814 E:818 ||| NNP
VLP  ||| S:818 E:822 ||| NNP
vaccine  ||| S:822 E:830 ||| NN
candidate  ||| S:830 E:840 ||| NN
was  ||| S:840 E:844 ||| VBD
generated  ||| S:844 E:854 ||| VBN
that  ||| S:854 E:859 ||| IN
protected  ||| S:859 E:869 ||| JJ
mice  ||| S:869 E:874 ||| NNS
and  ||| S:874 E:878 ||| CC
rats  ||| S:878 E:883 ||| NNS
against  ||| S:883 E:891 ||| IN
a  ||| S:891 E:893 ||| DT
lethal  ||| S:893 E:900 ||| JJ
RVFV  ||| S:900 E:905 ||| NNP
challenge ||| S:905 E:914 ||| NN
.  ||| S:914 E:916 ||| .
This  ||| S:916 E:921 ||| DT
was  ||| S:921 E:925 ||| VBD
followed  ||| S:925 E:934 ||| VBN
by  ||| S:934 E:937 ||| IN
the  ||| S:937 E:941 ||| DT
development  ||| S:941 E:953 ||| NN
and  ||| S:953 E:957 ||| CC
optimization  ||| S:957 E:970 ||| NN
of  ||| S:970 E:973 ||| IN
conditions  ||| S:973 E:984 ||| NNS
for  ||| S:984 E:988 ||| IN
production  ||| S:988 E:999 ||| NN
of  ||| S:999 E:1002 ||| IN
RVF  ||| S:1002 E:1006 ||| NNP
VLPs  ||| S:1006 E:1011 ||| NNP
in  ||| S:1011 E:1014 ||| IN
insect  ||| S:1014 E:1021 ||| NN
and  ||| S:1021 E:1025 ||| CC
mammalian  ||| S:1025 E:1035 ||| JJ
cells ||| S:1035 E:1040 ||| NNS
.  ||| S:1040 E:1042 ||| .
Immunological  ||| S:1042 E:1056 ||| JJ
studies  ||| S:1056 E:1064 ||| NNS
demonstrated  ||| S:1064 E:1077 ||| VBN
that  ||| S:1077 E:1082 ||| IN
VLP-based  ||| S:1082 E:1092 ||| JJ
vaccine  ||| S:1092 E:1100 ||| NN
candidates  ||| S:1100 E:1111 ||| NNS
elicit  ||| S:1111 E:1118 ||| VBP
both  ||| S:1118 E:1123 ||| DT
humoral  ||| S:1123 E:1131 ||| NN
and  ||| S:1131 E:1135 ||| CC
cellular  ||| S:1135 E:1144 ||| JJ
immune  ||| S:1144 E:1151 ||| JJ
responses ||| S:1151 E:1160 ||| NNS
.  ||| S:1160 E:1162 ||| .
Subsequent  ||| S:1162 E:1173 ||| JJ
challenge  ||| S:1173 E:1183 ||| NN
studies  ||| S:1183 E:1191 ||| NNS
using  ||| S:1191 E:1197 ||| VBG
a  ||| S:1197 E:1199 ||| DT
lethal  ||| S:1199 E:1206 ||| JJ
wild-type  ||| S:1206 E:1216 ||| JJ
RVFV  ||| S:1216 E:1221 ||| NNP
strain  ||| S:1221 E:1228 ||| NN
under  ||| S:1228 E:1234 ||| IN
high-containment  ||| S:1234 E:1251 ||| JJ
conditions  ||| S:1251 E:1262 ||| NNS
showed  ||| S:1262 E:1269 ||| VBD
that  ||| S:1269 E:1274 ||| IN
RVF  ||| S:1274 E:1278 ||| NNP
VLP  ||| S:1278 E:1282 ||| NNP
vaccine  ||| S:1282 E:1290 ||| NN
candidates  ||| S:1290 E:1301 ||| NNS
can  ||| S:1301 E:1305 ||| MD
completely  ||| S:1305 E:1316 ||| RB
protect  ||| S:1316 E:1324 ||| VB
mice  ||| S:1324 E:1329 ||| NNS
and  ||| S:1329 E:1333 ||| CC
rats ||| S:1333 E:1337 ||| NNS
.  ||| S:1337 E:1339 ||| .
